About Page

Gryphus Diagnostics, LLC was established in 1998 in Birmingham, AL as an innovative company focusing on the development and manufacture of rapid detection systems. The first of many of these new technologies was FDA released in May of 2000, leading the way for a host of other products undergoing investigation. In early 2003, Gryphus was issued a U.S. patent covering its sialidase technology platform.

Gryphus’ products are registered and/or have regulatory approval in several countries worldwide and marketed globally to point-of-care facilities, hospitals, and clinical laboratories through a network of established distributors and licensees. Through currently available products, investigational products awaiting release, and R & D effort promising future products, Gryphus is quickly becoming a recognized name in the medical device industry.

Gryphus’ primary objective is, and has always been, quality. To that end, the Company operates under very strict guidelines set forth by the FDA. The manufacturing plant is a cGMP facility with laboratories employing state-of-the-art equipment and highly trained, skilled individuals. This combination of an ideal scientific environment with expertise in a wide variety of disciplines has resulted in a synergistic explosion of advancements.